secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aspire Biopharma Holdings, Inc. (ASBP)
CIK:        0001847345
Form:       8-K
Filed at:   2026-04-16T23:59:59+00:00
Accession:  0001493152-26-017115
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aspire Biopharma closes $10M second tranche of Series A preferred offering; amends certificate
--------------------------------------------------------------------------------

- Second closing issued 12,500 Series A Convertible Preferred Shares for gross proceeds of $10,000,000.
- Combined with prior closing of 13,750 shares ($11M including $943,801 debt conversion), total 30,000 shares designated.
- Company believes stockholders' equity now exceeds $2.5M minimum for continued Nasdaq listing.
- Certificate of Amendment filed Apr 13, 2026 designating 30,000 Series A shares with $1,000 stated value each.
- Conversion price set at 80% of lowest closing price over 5 days before conversion; floor price at 20% of Nasdaq Minimum Price.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1847345/000149315226017115/0001493152-26-017115-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1847345/000149315226017115/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-017115

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer